Startseite News
News

Idecabtagene Vicleucel Leads to High Response Rates in Relapsed/Refractory Myeloma

17-12-2020 13:22

Three-quarters of patients with heavily pretreated multiple myeloma responded to treatment with the BCMA-targeted CAR T-cell therapy, according to phase I results.

Read more

 

Zurück

Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.